JAN 2 5 2001

510(k) Summary - Elecsys® HCG STAT CalSet II

Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter name, address, contact

Roche Diagnostics Corporation 9115 Hague Rd Indianapolis IN 46250 (317) 576-3544

Contact person: Kay A. Taylor

Date prepared: December 19, 2000

Predicate device

Roche Diagnostics Elecsys® HCG STAT CalSet II is substantially equivalent to other devices legally marketed in the United States. We claim equivalence to the currently marketed Roche Diagnostics Elecsys® HCG STAT CalSet.

Device description

Roche Diagnostics Elecsys® HCG STAT CalSet II consists of lyophilized human serum matrix with added HCG in two concentration ranges.

Intended use / Indication for use Roche Diagnostics Elecsys® HCG STAT CalSet II is intended for the calibration of the quantitative HCG STAT assay on the Elecsys® immunoassay analyzer systems.

Substantial equivalence

Elecsys® HCG STAT CalSet II is equivalent to other devices legally marketed in the United States. We claim equivalence to the currently marketed Roche Diagnostics Elecsys® HCG STAT CalSet cleared under document K961487.

510(k) Summary - Elecsys® HCG STAT CalSet II, continued

Substantial equivalence – similarities

The following table compares Elecsys® HCG STAT CalSet II, with the predicate device Elecsys® HCG STAT CalSet.

| Characteristic | Elecsys® HCG STAT CalSet II | Elecsys® HCG STAT CalSet |
|----------------|--|--|
| Intended Use | For the calibration of the quantitative HCG STAT assay on the Elecsys immunoassay systems. | For the calibration of the quantitative HCG STAT assay on the Elecsys immunoassay systems. |
| Levels | Two levels | Two levels |

Substantial equivalence -- differences --

| Characteristic | Elecsys® HCG STAT CalSet II | Elecsys® HCG STAT CalSet |
|----------------|---|---|
| Format | Lyophilized | Liquid |
| Matrix | Human serum matrix with added human HCG | Buffer/protein matrix with added human HCG |
| Stability | Unopened Stable at 2-8° C until expiration date Reconstituted: ✓ 2-8°C – 4 weeks ✓ On analyzer – 5 hours | Unopened Stable at 2-8° C until expiration date Reconstituted: ✓ 2-8°C – 12 weeks ✓ On analyzer – 5 hours |



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JAN 2 5 2001

Ms. Kay A. Taylor Regulatory Affairs, Laboratory Systems Roche Diagnostics Corporation 9115 Hague Road PO Box 50457 Indianapolis, Indiana 46250-0457

Re: I

K003941

Trade Name: Elecsys® HCG STAT CalSet II

Regulatory Class: II Product Code: JIS

Dated: December 19, 2000 Received: December 21, 2000

Dear Ms. Taylor:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven I. Gutman, M.D., M.B.A.

Director

Division of Clinical Laboratory Devices

Steven Butman

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

INDICATIONS FOR USE STATEMENT

| 510(k) Number (if known):- N/A- K003941 |
|--|
| Device Name: Elecsys® HCG STAT CalSet II |
| Indications For Use: |
| For the calibration of the quantitative HCG STAT assay on the Elecsys® Immunoassay analyzer systems. |
| |
| (Division Sign-Off) Division of Clinical Laboratory Devices 510(k) Number 60 374 |
| (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) |
| Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use OR Over-The-Counter Use (Per 21 CFR 801.109) (Optional Format 1-2-96) |